Dyskinesia during treatment with duloxetine [2]

Pharmacopsychiatry

Volumn 39, Issue 6, 2006, Pages 237-238

  Deuschle, Michael ^a   Mase, E ^a   Zink, M ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; DULOXETINE; IMIPRAMINE; MOOD STABILIZER; QUETIAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AKATHISIA; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HAMILTON SCALE; HUMAN; INVOLUNTARY MOVEMENT; LETTER; MONOTHERAPY; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA, PARANOID; THIOPHENES;

EID: 33845381112     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951608     Document Type: Letter

References (10)

1. an der Heiden W, Konnekce R, Maurer K, Ropeter D, Häfner H. Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 255: 174-184
2. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32: 692-698
3. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004; 161 (suppl 2): 1-56
4. Leo R. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-454
5. Mazeh D, Shalal B, Saraf R, Melamed Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. J Clin Psychopharmacol 2004; 24: 653-655
6. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol 2003; 17: 107-112
7. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297-302
8. Raedler TJ, Jahn H, Arlt J, Kiefer F, Schick M, Naber D, Wiedemann K. Adjunctive use of reboxetine in schizophrenia. A controlled trial. J Assoc Europ Psychiatr 2004; 19: 366-369
9. Siris SG, Bermanzohn PC, Mson SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994; 51: 109-115
10. Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine treatment of major depressive episodes in the course of psychotic disorders. Pharmacopsychiatry 2006; 39: 109-111